Pink Sheets No Information
Last reported O/S 51,223,991 (June 30, 2007)
Last reported A/S 300,000,000 (June 30, 2007)
Current Market Cap: $97,300 (February 26, 2010)
From their last SEC filing:
IQ Micro Inc. is an international licensing company that commercializes proprietary technology developed for use in the microfluidics sector. Developed from the micro-chip industry, microfluidics involves circuits of tiny chambers, channels and pumps that direct the flow of liquids on a single micro-chip.
IQ Micro is actively pursuing global licensing opportunities for its patented electro-osmotic membrane technology and its "invisible pump," a microfluidic technology with a wide range of consumer, medical and industrial applications. With its proprietary technology and highly experienced management, IQ Micro expects to become a leading global, specialized supplier of low-voltage microfluidic technology.
2223 Raleigh St.
Denver, CO 80219
Partnership between IQMC and Osmotex:
On June 9, 2005, the Company (IQ Micro) commenced development activities when it acquired exclusive, worldwide sales and marketing licensing rights to microfluidics technology developed and patented by Osmotex AS ("Osmotex"), incorporated in Norway in 1999, as well as additional intellectual property rights of Osmotex together with such patents, (the "Licensed Rights").
Who is Osmotex?
From their website:
Osmotex is an innovative company dedicated to delivering the most advanced and useful pumps for the emerging science and technology of microfluidics. We produce generic micropumps for fuel cells, life-sciences and chemical research, and do also engage in application specific development with partners.
Osmotex AG is located together with its long term research partner, the Swiss Center of Electronics and Microtechnology (CSEM) in Central Switzerland. Osmotex' research started at the Norwegian Institute of Science and Technology (NTNU) in 1999.
Caption: Dr. Tormod Volden of Osmotex working with Dr. Helmut Knapp of CSEM.
Osmotex's Patent Porfolio:
8/13/09 - ELECTRO-OSMOTIC PUMP
2/26/09 - TEXTILE HAVING WATER TRANSPORT AND HEATING CAPABILITIES
http://www.wipo.int/pctdb/en/fetch.jsp?LANG=ENG&DBSELECT=PCT&SERVER_TYPE=19-10&SORT=41269125-KEY&TYPE_FIELD=256&IDB=0&IDOC=585802&C=10&ELEMENT_SET=B&RESULT=1&TOTAL=1&START=1&DISP=25&FORM=SEP-0/HITNUM,B-ENG,DP,MC,AN,PA,ABSUM-ENG&SEARCH_IA=GB2008002815&QUERY=(FP/osmolife)+ (through parent company Osmolife)
1/22/04 - ACTUATOR IN A MICROFLUIDIC SYSTEM FOR INDUCING ELECTROOSMOTIC LIQUID MOVEMENT IN A MICRO CHANNEL
1/22/04 - FABRIC MATERIAL WITH IMPROVED LIQUID TRANSPORT
Here is more information on one investment company which has invested in Osmotex:
Jade Invest SA
Slide Show published 3 months ago:
Article from San Diego Business Site mentions Jade Invest SA (December 24, 2009):
Banque Bonhôte invests CHF 20 million in the capital of Jade SA (October 1, 2009):
What have they been up to lately?
Articles concerning developments at Osmotex:
"Using electrokinesis is the trick with advanced micro-pumps" - Innovation Journal
"Battery or Superfluous Battery" - Handelszeitung & The Wall Street Journal
What products do they currently have available?
Screenshot of products page (first line of products):
Marketing material for their first line of products:
Two videos of their products:
Textile Micro-pump: http://www.osmotex.ch/en/products/textile_pump/
Partnership between IQMC and Lifecare AS:
IQ Micro Inc. (OTCBB: IQMC), exclusive licensor of patented electro-osmotic membranes and micro-pumps for the rapidly emerging microfluidic technologysector, announced today that its parent company, Osmotex AS, has merged with Lifecare AS, a private Norwegian company developing advanced micro and nanotechnology for the diabetes monitoring market. The expanded parent company, renamed Osmolife AS, will continue to function as a holding company for two research and development subsidiaries and for IQ Micro, its exclusive, worldwide sales and marketing company.
Lifecare AS is focused on developing the next generation of glucose devices.
For more information on the field of Biomedical Sensors and it's relation to Lifecare this is an interesting article:
Kelvin Nanotechnologies, University of Glasgow (Scotland)
University of Oslo, Institute of Informatics (Norway)
Rikshospitalet University Hospital, Institute of Immunology (Norway)
VTT Institute of Technology (Finland)
Vestfold University College (Norway)
Lifecare's Patent Portfolio
2/26/09 - APPARATUS AND METHOD FOR MEASURING AUGMENTED OSMOTIC PRESSURE IN A REFERENCE CAVITY
9/12/08 - FABRICATION OF REINFORCED NANOPOROUS MEMBRANES
12/16/04 - SENSOR IN VIVO MEASUREMENT OF OSMOTIC CHANGES
1/21/00 - SELF-DESTRUCTING NEEDLE HOLDER FOR INJECTION SYRINGES OR THE LIKE
5/28/99 - ARRANGEMENT IN A NEEDLE HOLDER FOR A SELF-DESTRUCTING SYRINGE
8/13/98 - SELF-DESTRUCTING HYPODERMIC SYRINGE
7/15/98 - METHOD FOR MONITORING THE LEVEL OF AN OSMOTICALLY ACTIVE COMPONENT IN BODY FLUID AND DEVICE FOR CARRYING OUT SAID METHOD
$2 million grant from the Research Council of Norway:
What have they been up to lately?
A few months ago, at the beginning of November 2009 there was the Diabetes Technology Society Meeting in Brussels, Belgium. At the meeting Lifecare AS presented Sencell, a new glucose monitoring device they have been working on. Press on Lifecare after the conference:
Latest Sencell Developments:
The prototypes of the SENCELL are in October 2009 going through laboratory in vitro testing to verify performance data.
What is Sencell?
Here's how it works. First a small chip is inserted into the skin using a syringe. It is a few millimeters big and serves as a glucose sensor. The way it is able to gauge glucose levels is osmotic pressure using Osmotex's microfluidics technology. Based on this technology and the initial buzz it has been receiving you can see how this basic premise could be expanded out beyond just glucose devices.
Here is an excerpt from some press:
Injectable Continuous Ostomotic Glucose Sensor – LifeCare AS out of Bergen, Norway, is working on a CGM that’s so tiny it can be implanted without surgery. The product is called SENCELL, and will be injected under the skin on your wrist. The technology is based on osmotic pressure, but please don’t ask me to explain the science behind it; something about a “reversible competitive affinity assay” that recognizes changes in glucose levels, and then wirelessly transmits them to an external receiver. All I know now is that the company claims it’s the “new frontier in CGM!” SENCELL is currently undergoing laboratory in vitro testing to determine reactions from the immune system. Hmmm.
According to the following PR, Lifecare and Osmotex were put under the umbrella of a parent company Osmolife.
IQ Micro Inc. (OTCBB: IQMC), exclusive licensor of patented electro-osmotic membranes and micro-pumps for the rapidly emerging microfluidic technology sector, announced today that its parent company, Osmotex AS, has merged with Lifecare AS, a private Norwegian company developing advanced micro and nanotechnology for the diabetes monitoring market. The expanded parent company, renamed Osmolife AS, will continue to function as a holding company for two research and development subsidiaries and for IQ Micro, its exclusive, worldwide sales and marketing company.
IQMC may have acquired Lifecare AS's outstanding shares:
IQ Micro Inc., exclusive licensor of patented electro-osmotic membranes and micro-pumps for the microfluidic technology sector, has entered an agreement in principle with its parent company, Osmolife AS, to acquire all of the issued and outstanding shares of Lifecare AS. A private Norwegian company, Lifecare is developing advanced micro and nanotechnology for the diabetes monitoring market. The proposed transaction is scheduled to close on July 15, 2007.
IQ Micro President and CEO, Johnny Christiansen, said, "With this acquisition, IQ Micro will strengthen its position in the $11 billion worldwide diabetes market by gaining immediate access to the parent company's proprietary technologies. As we continue to commercialize our licensed microfluidics technologies, Lifecare's patented technology will create another important building block in the future of diabetes treatment for the company."
Lifecare has been developing an implantable osmotic sensor for automated, continuous glucose monitoring. The company's proprietary sensor, SENCELL, promises precision and accuracy beyond existing solutions. SENCELL integrates micro and nanofabrication technologies into a tiny device that provides a platform for development of a long-term, in vivo glucose sensor solution to replace conventional, less efficient glucose monitoring and measurement techniques.